Th1 vaccination priming for active immunotherapy

A method of reducing cancer recurrence in an individual comprising:

• developing an anti-alloantigen immunity in the individual when the individual is in remission and not exhibiting symptoms from the cancer by administering a priming composition causing increased Th1 anti-alloantigen specific titer in circulation by the individual's immune system, the priming composition comprising allogeneic activated Th1 memory cells and cross-linking agents for cross-linking the CD3 and CD28 surface moieties on the Th1 memory cells, wherein the allogeneic Th1 memory cells are derived from healthy donor blood and are activated by the cross-linking of CD3 and CD28 surface molecules at the time of administration, wherein administration of the priming composition causes increased Th1 anti-alloantigen specific titer in circulation, wherein the anti-alloantigen immunity is developed in the individual prior to administration of cancer-related antigens;
• administering one or more cancer-related antigens to the primed individual, wherein the priming composition and the one or more cancer-related antigens are administered prior to cancer recurrence in the individual;
• and
• activating the anti-alloantigen immunity of the individual by administering an activating composition comprising allogeneic activated Th1 memory cells when the individual develops symptoms of the cancer, wherein the activating composition further comprises one or more cancer-related antigens.